Dénes Csonka

640 total citations
14 papers, 464 citations indexed

About

Dénes Csonka is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Dénes Csonka has authored 14 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 5 papers in Molecular Biology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Dénes Csonka's work include Pulmonary Hypertension Research and Treatments (5 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Phosphodiesterase function and regulation (2 papers). Dénes Csonka is often cited by papers focused on Pulmonary Hypertension Research and Treatments (5 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Phosphodiesterase function and regulation (2 papers). Dénes Csonka collaborates with scholars based in Switzerland, United States and Belgium. Dénes Csonka's co-authors include Malte Peters, Heidi Nauwelaerts, Cristiana Sessa, David Demanse, Zev A. Wainberg, Ngocdiep T. Le, Josep Tabernero, Philippe L. Bédard, Anastasios Stathis and Filip Jankú and has published in prestigious journals such as Clinical Cancer Research, Journal of the American Society of Nephrology and European Journal of Cancer.

In The Last Decade

Dénes Csonka

14 papers receiving 461 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dénes Csonka Switzerland 5 231 191 148 80 70 14 464
K. Nathan Sankar United States 14 124 0.5× 170 0.9× 269 1.8× 74 0.9× 80 1.1× 41 526
Fangfang Lü China 3 151 0.7× 217 1.1× 238 1.6× 72 0.9× 85 1.2× 4 458
Marilyn Mulay United States 11 243 1.1× 250 1.3× 365 2.5× 37 0.5× 104 1.5× 17 644
Lingzhi Hong United States 12 213 0.9× 238 1.2× 216 1.5× 35 0.4× 115 1.6× 28 487
Shoichiro Mukai Japan 12 173 0.7× 111 0.6× 117 0.8× 102 1.3× 97 1.4× 54 438
Olugbenga Olowokure United States 14 162 0.7× 156 0.8× 269 1.8× 61 0.8× 98 1.4× 35 513
Johann Raats South Africa 9 188 0.8× 280 1.5× 367 2.5× 48 0.6× 83 1.2× 15 569
Martina Makrutzki Spain 8 268 1.2× 285 1.5× 500 3.4× 66 0.8× 105 1.5× 14 699
Shinji Nakamichi Japan 13 238 1.0× 268 1.4× 281 1.9× 34 0.4× 88 1.3× 51 566
Jinhyun Cho South Korea 14 126 0.5× 185 1.0× 498 3.4× 18 0.2× 62 0.9× 37 775

Countries citing papers authored by Dénes Csonka

Since Specialization
Citations

This map shows the geographic impact of Dénes Csonka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dénes Csonka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dénes Csonka more than expected).

Fields of papers citing papers by Dénes Csonka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dénes Csonka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dénes Csonka. The network helps show where Dénes Csonka may publish in the future.

Co-authorship network of co-authors of Dénes Csonka

This figure shows the co-authorship network connecting the top 25 collaborators of Dénes Csonka. A scholar is included among the top collaborators of Dénes Csonka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dénes Csonka. Dénes Csonka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Ayyar, Vivaswath S., Shohei Ouchi, Elisa Fabbrini, et al.. (2024). Preclinical and Clinical Pharmacokinetics of JNJ‐75220795, an siRNA Therapeutic Targeting PNPLA3, for Metabolic Dysfunction‐Associated Steatohepatitis. The Journal of Clinical Pharmacology. 65(5). 644–653. 2 indexed citations
2.
Ford, Jennifer Lynn, Jaya Natarajan, Hans Stieltjes, et al.. (2024). Bioequivalence and the food effect of macitentan/tadalafil 10/20 fixed‐dose combination tablets versus the use of single‐component tablets in healthy subjects. Pharmacology Research & Perspectives. 12(3). e1202–e1202. 2 indexed citations
3.
Dinh, Alex, Victor Dishy, Jason R. Waggoner, et al.. (2023). First-in-Human Study of an mTORC1-Selective Inhibitor for the Treatment of ADPKD. Journal of the American Society of Nephrology. 34(11S). 206–206. 1 indexed citations
4.
Bartolucci, Roberta, Anne‐Gaëlle Dosne, Dénes Csonka, et al.. (2021). A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension. Clinical Pharmacokinetics. 60(12). 1605–1619. 3 indexed citations
5.
Csonka, Dénes, Jaya Natarajan, Hans Stieltjes, et al.. (2021). Bioequivalence and food effect of a fixed‐dose combination of macitentan and tadalafil: Adaptive design in the COVID‐19 pandemic. Pharmacology Research & Perspectives. 9(5). e00846–e00846. 3 indexed citations
6.
Sidharta, Patricia N., et al.. (2020). Relative bioavailability of a pediatric dispersible tablet and adult film‐coated tablet of macitentan in healthy volunteers. Pharmacology Research & Perspectives. 8(2). e00580–e00580. 3 indexed citations
7.
Grill, Simon, Shirin Bruderer, Patricia N. Sidharta, et al.. (2020). Bioequivalence of macitentan and tadalafil given as fixed‐dose combination or single‐component tablets in healthy subjects. British Journal of Clinical Pharmacology. 86(12). 2424–2434. 8 indexed citations
8.
Csonka, Dénes, et al.. (2019). Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects. Clinical Drug Investigation. 39(12). 1223–1232. 4 indexed citations
9.
Sitbon, Olivier, Jaime Bosch, Emmanuelle Cottreel, et al.. (2019). Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. The Lancet Respiratory Medicine. 7(7). 594–604. 111 indexed citations
10.
Massard, Christophe, Kim Nguyen, Daniel Castellano, et al.. (2017). Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. European Journal of Cancer. 76. 36–44. 64 indexed citations
11.
Csonka, Dénes, et al.. (2015). A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment. The Journal of Clinical Pharmacology. 56(3). 316–323. 3 indexed citations
12.
Chi, K.N., Daniel Castellano, Johann S. de Bono, et al.. (2015). 2550 Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC). European Journal of Cancer. 51. S493–S493. 1 indexed citations
13.
Bédard, Philippe L., Josep Tabernero, Filip Jankú, et al.. (2014). A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. Clinical Cancer Research. 21(4). 730–738. 257 indexed citations
14.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K. Nathan Sankar Breakdown of academic impact, for papers by Fangfang Lü Breakdown of academic impact, for papers by Marilyn Mulay Breakdown of academic impact, for papers by Lingzhi Hong Breakdown of academic impact, for papers by Shoichiro Mukai Breakdown of academic impact, for papers by Olugbenga Olowokure Breakdown of academic impact, for papers by Johann Raats Breakdown of academic impact, for papers by Martina Makrutzki Breakdown of academic impact, for papers by Shinji Nakamichi Breakdown of academic impact, for papers by Jinhyun Cho
Rankless by CCL
2026